Prometrium® (progesterone) 400mg soft vaginal capsules
Prometrium is for the prevention of miscarriage in women with a history of recurrent miscarriage who present with bleeding in the first trimester.¹
Understanding recurrent miscarriage
It takes a great deal of personal strength and resilience to continue trying for a baby after pregnancy loss — especially if it isn’t the first time it’s happened.
In a literature review of nine studies from Europe and North America, compared to women with no previous history of miscarriage (11%), the risk of miscarriage increases by around 10% for each additional miscarriage, reaching 42% in women with three or more previous miscarriages.2
Beyond being prescribed treatment that may increase the chance of a successful pregnancy after recurrent miscarriages3,4 these parents and their loved ones need support to help mitigate the impact of anxiety, and to promote a positive and hopeful mindset when trying again.
Learn more about miscarriage by clicking through to the page below.
About Prometrium
Prometrium is the UK’s first and only licensed progesterone treatment for the prevention of miscarriage in women with a history of recurrent miscarriage who present with bleeding in the first trimester.1
The recommended dose is 400 mg administered vaginally, twice a day (morning and night). Treatment should be initiated during the first trimester of pregnancy, at first sign of vaginal bleeding and should continue to the 16th week of gestation.1
Why prescribe Prometrium?
Prometrium is the first and only licensed progesterone treatment for the prevention of miscarriage in women with a history of recurrent
miscarriage who present with bleeding in the first trimester.1
Prometrium may help these patients achieve a successful pregnancy, and our resources offer a range of online content designed to answer common patient questions.
If you are a healthcare professional with formulary or budgetary responsibility and want some support on decision-making in your healthcare setting, access the Prometrium formulary pack via our educational resources page.
When is Prometrium prescribed?
Prometrium 400mg may be prescribed to women with a history of recurrent miscarriage, at the first sign of vaginal bleeding during the first trimester of pregnancy.¹
Treatment should always be individualised to the patient. A complete medical examination must be performed before starting the treatment and regularly during the treatment. The decision to treat women who have experienced recurrent miscarriages should follow further investigation and is at the discretion of the clinician.¹
The recommended dose is 400 mg twice a day (morning and night). Treatment should be initiated during the first trimester of pregnancy, at first sign of vaginal bleeding and should continue to the 16th week of gestation.¹
To support prescribing within your healthcare setting, you can download the Prometrium formulary pack below.
Please consider information about special warnings, precautions and contraindications.
Prometrium 400mg soft vaginal capsules contains soybean lecithin and may cause hypersensitivity reactions (urticarial and anaphylactic shock in hypersensitive patients). As there is a possible relationship between allergy to soya and allergy to peanut, patients with peanut allergy should avoid using Prometrium 400mg soft vaginal capsules.¹
Please consult the Summary of Product Characteristics for further information.
NICE, RCOG and ESHRE guidance support the use of progesterone in women presenting with bleeding in the first trimester of pregnancy with a history of recurrent miscarriage.8,9
Abbreviations
References
- Prometrium 400mg soft vaginal capsules Summary of Product Characteristics. Available at:
https://www.medicines.org.uk/emc/product/16016/smpc. Accessed April 2026 - Quenby S, et al. Lancet. 2021;397(10285):1658–67.
- Coomarasamy A, et al. Am J Obstet Gynecol. 2020;223(2):167–176.
- Devall AJ, et al. Cochrane Database Syst Rev. 2021:4.
- Austin L, et al. Camb Q Healthc Ethics. 2021;30(1):175–87.
- NICE 2021 Ectopic pregnancy and miscarriage: diagnosis and initial management (NG126). Available at:
https://www.nice.org.uk/guidance/ng126.Accessed April 2026 - Regan L, Rai R, Saravelos S, Li T-C, on behalf of the Royal College of Obstetricians and Gynaecologists. Recurrent Miscarriage: Green-top Guideline No. 17. BJOG. 2023; 130(12): e9–e39.
- ESHRE guideline: recurrent pregnancy loss. Update 2022, can be accessed from https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Recurrent-pregnancy-loss.aspx
https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Recurrent-pregnancy-loss.aspxAccessed April 2026
Adverse event reporting
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd Drug Safety on 0203 862 0920 or Email: drugsafety@besins-healthcare.com